Table 2.
Clinical and laboratory characteristics of the control group and differentiated thyroid cancer patients receiving long-term (5 to 9 years) levothyroxine suppression therapy.
| Parameters | Cancer group (n = 14) | Control patients (n = 14) | P value |
|---|---|---|---|
| Age (years) | 42.9 ± 7.2 | 42.9 ± 6.5 | 0.637 |
| BMI (kg/m2) | 23.1 ± 2.1 | 23.5 ± 1.8 | 0.198 |
| Heart rate (beats/min) | 68.0 ± 9.3 | 66.1 ± 8.1 | 0.484 |
| SBP (mmHg) | 116.4 ± 10.6 | 118.6 ± 12.9 | 0.662 |
| DBP (mmHg) | 75.7 ± 6.2 | 76.4 ± 9.3 | 0.819 |
| TSH (mU/L) | 0.06 ± 0.03 | 1.58 ± 1.29 | 0.001 |
| Free T4 (pmol/L) | 19.7 ± 5.2 | 11.5 ± 2.4 | 0.002 |
| Free T3 (pmol/L) | 4.4 ± 0.3 | 4.3 ± 0.2 | 0.730 |
| NT-pro-BNP (pg/mL) | 59.2 ± 50.3 | 38.0 ± 19.4 | 0.198 |
Data are expressed as mean ± standard deviation. P values are calculated by Mann-Whitney test. BMI, body mass index; DBP, diastolic blood pressure; SBP, systolic blood pressure; TSH, thyroid-stimulating hormone.